Purple Biotech

Historical price data

Purple Biotech Ltd. is an Israeli, NASDAQ-listed biotech focused on developing next-generation oncology therapeutics. Its mission is to counteract the primary mechanisms of cancer treatment failure—immune evasion and drug resistance—through targeted agents like the anti-CEACAM1 mAb CM24 and the dual inhibitor NT219. The company's strategy centers on advancing these clinical-stage assets in combination regimens to demonstrate proof-of-concept and unlock significant value. As a micro-cap entity, its near-term trajectory is heavily dependent on clinical readouts from its Phase 2 studies.

Purple Biotech's platform is a mechanistic focus on targeting key pathways of tumor immune evasion (CEACAM1 checkpoint) and adaptive drug resistance (dual inhibition of IRS1/2 and STAT3 signaling nodes).

CM24 competes in the crowded immuno-oncology space but is differentiated by its novel CEACAM1 target. NT219 faces competition from other resistance-overcoming agents but is unique in its dual IRS1/2-STAT3 inhibition strategy. Both programs require clear clinical differentiation to succeed.